ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on August 28, 2024. The filing addresses regulatory compliance matters regarding the company's listing on the Nasdaq Capital Market.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantitative data disclosed is the share count:
- Common Stock Outstanding: 17,280,655 shares (as of August 28, 2024).
Material Changes
The primary event reported is the receipt of an extension from a Hearing Panel of the Nasdaq Stock Market LLC. This extension allows the company additional time to regain compliance with the Nasdaq minimum bid price requirement for continued listing.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) regarding the listing extension but does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the immediate listing compliance issue. The information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific duration of the Nasdaq compliance extension granted.
- Review the attached Press Release (Exhibit 99.1) for details on the minimum bid price requirement and the company's plan to achieve compliance.
- Monitor the company's stock price to ensure it meets the minimum bid threshold before the extension expires.
- Confirm the current share count of 17,280,655 against subsequent filings for any dilution or buybacks.